These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32203145)

  • 21. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.
    Feng L; Sun X; Csizmadia E; Han L; Bian S; Murakami T; Wang X; Robson SC; Wu Y
    Neoplasia; 2011 Mar; 13(3):206-16. PubMed ID: 21390184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
    Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
    Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The abnormal function of CD39
    Lu Y; Cheng L; Li F; Ji L; Shao X; Wu B; Zhan Y; Liu C; Min Z; Ke Y; Sun L; Chen H; Cheng Y
    Ann Hematol; 2019 Aug; 98(8):1845-1854. PubMed ID: 31154474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.
    Mandapathil M; Szczepanski MJ; Szajnik M; Ren J; Lenzner DE; Jackson EK; Gorelik E; Lang S; Johnson JT; Whiteside TL
    Clin Cancer Res; 2009 Oct; 15(20):6348-57. PubMed ID: 19825957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
    Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
    J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adenosinergic Immunosuppression by Human Mesenchymal Stromal Cells Requires Co-Operation with T cells.
    Kerkelä E; Laitinen A; Räbinä J; Valkonen S; Takatalo M; Larjo A; Veijola J; Lampinen M; Siljander P; Lehenkari P; Alfthan K; Laitinen S
    Stem Cells; 2016 Mar; 34(3):781-90. PubMed ID: 26731338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression.
    Borsellino G; Kleinewietfeld M; Di Mitri D; Sternjak A; Diamantini A; Giometto R; Höpner S; Centonze D; Bernardi G; Dell'Acqua ML; Rossini PM; Battistini L; Rötzschke O; Falk K
    Blood; 2007 Aug; 110(4):1225-32. PubMed ID: 17449799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extracellular ATP inhibits IL-1-induced MMP-1 expression through the action of CD39/nucleotidase triphosphate dephosphorylase-1 on human gingival fibroblasts.
    Nemoto E; Gotoh K; Tsuchiya M; Sakisaka Y; Shimauchi H
    Int Immunopharmacol; 2013 Nov; 17(3):513-8. PubMed ID: 23941770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy.
    Schäkel L; Mirza S; Winzer R; Lopez V; Idris R; Al-Hroub H; Pelletier J; Sévigny J; Tolosa E; Müller CE
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD39 expression on Treg and Th17 cells is associated with metabolic factors in patients with type 2 diabetes.
    Cortez-Espinosa N; Cortés-Garcia JD; Martínez-Leija E; Rodríguez-Rivera JG; Barajas-López C; González-Amaro R; Portales-Pérez DP
    Hum Immunol; 2015 Sep; 76(9):622-30. PubMed ID: 26386144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis.
    Fletcher JM; Lonergan R; Costelloe L; Kinsella K; Moran B; O'Farrelly C; Tubridy N; Mills KH
    J Immunol; 2009 Dec; 183(11):7602-10. PubMed ID: 19917691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression.
    Bono MR; Fernández D; Flores-Santibáñez F; Rosemblatt M; Sauma D
    FEBS Lett; 2015 Nov; 589(22):3454-60. PubMed ID: 26226423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory T cells regulate the distribution of natural killer T cells through CD39 signal transduction in asthma.
    Lu Y; Li Y; Zhou W; Ding B; Yu Q
    Hum Cell; 2019 Apr; 32(2):141-149. PubMed ID: 30539423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased Frequency of Intestinal CD39
    Libera J; Wittner M; Kantowski M; Woost R; Eberhard JM; de Heer J; Reher D; Huber S; Haag F; Schulze Zur Wiesch J
    Front Immunol; 2020; 11():567472. PubMed ID: 33072107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population.
    Moncrieffe H; Nistala K; Kamhieh Y; Evans J; Eddaoudi A; Eaton S; Wedderburn LR
    J Immunol; 2010 Jul; 185(1):134-43. PubMed ID: 20498355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-27 confers a protumorigenic activity of regulatory T cells via CD39.
    Park YJ; Ryu H; Choi G; Kim BS; Hwang ES; Kim HS; Chung Y
    Proc Natl Acad Sci U S A; 2019 Feb; 116(8):3106-3111. PubMed ID: 30718407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD39 is upregulated during activation of mouse and human T cells and attenuates the immune response to Listeria monocytogenes.
    Raczkowski F; Rissiek A; Ricklefs I; Heiss K; Schumacher V; Wundenberg K; Haag F; Koch-Nolte F; Tolosa E; Mittrücker HW
    PLoS One; 2018; 13(5):e0197151. PubMed ID: 29742141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of nucleoside [correction of nucleotide] triphosphate diphosphohydrolase-1 (NTPDase-1)cd39 in xenograft rejection.
    Imai M; Takigami K; Guckelberger O; Enjyoji K; Smith RN; Lin Y; Csizmadia E; Sévigny J; Rosenberg RD; Bach FH; Robson SC
    Mol Med; 1999 Nov; 5(11):743-52. PubMed ID: 10656876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: effects on Rho-GTPase and adenosine nucleotide metabolism.
    Kaneider NC; Egger P; Dunzendorfer S; Noris P; Balduini CL; Gritti D; Ricevuti G; Wiedermann CJ
    Arterioscler Thromb Vasc Biol; 2002 Jun; 22(6):894-900. PubMed ID: 12067895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4
    Han L; Sugiyama H; Zhang Q; Yan K; Fang X; McCormick TS; Cooper KD; Huang Q
    Australas J Dermatol; 2018 Feb; 59(1):e31-e38. PubMed ID: 28295154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.